Table 1 Baseline characteristics of the lenvatinib plus pembrolizumab and re-challenge PT cohorts, before and after PSM
Before match | After Matched | |||||
|---|---|---|---|---|---|---|
Lenvatinib + Pembrolizumab N = 397 | Re-challenge PT N = 469 | p-value | Lenvatinib + Pembrolizumab N = 334 | Re-challenge PT N = 334 | p-value | |
Age at index* | 66.8 | 65.5 | 0.04 | 66.8 | 66.8 | 0.99 |
 < 65 years | 145 (37) | 185 (39) | 0.38 | 125 (37) | 116 (35) | 0.42 |
≧65 years | 252 (64) | 284 (61) | 0.38 | 209 (63) | 218 (65) | 0.42 |
Race | ||||||
White | 250 (63) | 311 (66) | 0.31 | 206 (62) | 224 (67) | 0.14 |
African-American | 76 (19) | 65 (14) | 0.04 | 62 (19) | 49 (15) | 0.19 |
Asian | 21 (5) | 19 (4) | 0.39 | 19 (6) | 13 (4) | 0.29 |
Unknown | 49 (12) | 64 (14) | 0.57 | 46 (14) | 45 (14) | 0.90 |
Charlson Comorbidity Index score* | 8.4 | 8.8 | 0.06 | 8.6 | 8.7 | 0.82 |
History of irradiation* | 183 (46) | 118 (25) |  < 0.001 | 123 (37) | 114 (34) | 0.29 |
Prior lines of therapy received before designated treatment* | ||||||
One line | 397 (100) | 469 (100) | NA | 334 (100) | 334 (100) | NA |
Two lines | 206 (52) | 160 (34) |  < 0.001 | 147 (44) | 147 (44) | 1 |
Therapies received before designated treatment | ||||||
Carboplatin | 397 (100) | 469 (100) | NA | 334 (100) | 334 (100) | NA |
Paclitaxel | 397 (100) | 469 (100) | NA | 334 (100) | 334 (100) | NA |
Docetaxel | 18 (5) | 19 (4) | 0.73 | 17 (5) | 17 (5) | 1 |
Doxorubicin | 58 (15) | 58 (12) | 0.33 | 38 (11) | 53 (16) | 0.08 |
Liposomal- doxorubicin | 35 (9) | 38 (8) | 0.71 | 25 (8) | 35 (11) | 0.17 |
Bevacizumab | 86 (22) | 84 (18) | 0.17 | 65 (20) | 69 (21) | 0.69 |
Sites of metastasis | ||||||
Lymph node | 185 (47) | 182 (39) | 0.02 | 152 (46) | 139 (42) | 0.30 |
Para-aortic LN | 88 (22) | 93 (20) | 0.40 | 69 (21) | 67 (20) | 0.85 |
Pelvic LN | 100 (25) | 86 (18) | 0.01 | 80 (24) | 66 (20) | 0.17 |
Lung | 81 (20) | 95 (20) | 0.96 | 67 (20) | 75 (23) | 0.45 |
Liver | 67 (17) | 89 (19) | 0.42 | 53 (16) | 55 (17) | 0.83 |
Peritoneum | 169 (43) | 280 (60) |  < 0.001 | 154 (46) | 188 (56) | 0.01 |
Colorectal | 47 (12) | 81 (17) | 0.03 | 42 (13) | 54 (16) | 0.20 |